Cours Tilray, Inc. London S.E.
Actions
0UI4
CA03765K1049
Produits pharmaceutiques
CA 2024 * | 784 M 1,07 Md 692 M | CA 2025 * | 866 M 1,18 Md 764 M | Capitalisation | 1,59 Md 2,18 Md 1,41 Md |
---|---|---|---|---|---|
Résultat net 2024 * | -217 M -297 M -192 M | Résultat net 2025 * | -69 M -94,39 M -60,9 M | VE / CA 2024 * | 2,37 x |
Dette nette 2024 * | 264 M 361 M 233 M | Dette nette 2025 * | 319 M 436 M 282 M | VE / CA 2025 * | 2,21 x |
PER 2024 * |
-5,98
x | PER 2025 * |
-19,8
x | Employés | 1 600 |
Rendement 2024 * |
-
| Rendement 2025 * |
-
| Flottant | 98,76% |
Dernier transcript sur Tilray, Inc.
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 30/04/21 |
Carl Merton
DFI | Director of Finance/CFO | - | 30/04/21 |
Lloyd Brathwaite
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/21 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Irwin Simon
CEO | Chief Executive Officer | 65 | 30/04/21 |
David Clanachan
BRD | Director/Board Member | 62 | 30/04/21 |
Walter Robb
BRD | Director/Board Member | 70 | 30/04/21 |
Varia. 1 janv. | Capi. | |
---|---|---|
+55,35% | 848 Md | |
+31,64% | 627 Md | |
-0,10% | 363 Md | |
+15,47% | 318 Md | |
+13,10% | 299 Md | |
+15,51% | 243 Md | |
+16,72% | 225 Md | |
+16,54% | 179 Md | |
+4,31% | 167 Md |